FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023647184> ?p ?o ?g. }

• W2023647184 endingPage "548" @default.
• W2023647184 startingPage "535" @default.
• W2023647184 abstract "Background The role of erythropoiesis-stimulating agents (ESAs) in treating the anemia of chronic kidney disease has been reevaluated in view of recent studies suggesting that the use of these agents may be associated with increased morbidity and mortality. This potential increased risk needs to be weighed against the potential benefit of ESAs in improving various aspects of health-related quality of life, in particular, exercise tolerance and physical functioning. Study Design A systematic review and meta-analysis of exercise tolerance and physical functioning. Setting & Participants Adults on maintenance dialysis therapy. Selection Criteria for Studies Outcomes measured before and after ESA treatment were required. Studies of physical function were required to include at least 25 participants. Intervention Treatment with any ESA. Outcomes Exercise tolerance measured using VO2peak (oxygen consumption per minute at the peak workload during the test), duration of exercise, or 6-minute walk distance or physical functioning assessed using ≥ 1 patient- or clinician-reported outcome measure that included a physical function domain. Results 28 articles met criteria for inclusion for evaluation of exercise tolerance, and 14 articles, for physical function. Meta-analysis showed a 23.8% increase in VO2peak from before to after erythropoietin therapy initiation (15 studies) and a nonsignificant 8.2% increase comparing a higher with a lower hemoglobin target (3 studies). For physical functioning, 4 studies met criteria for inclusion in the meta-analysis: there was a 10.5% increase in Karnofsky score from before to after erythropoietin therapy initiation. Limitations Many studies of exercise tolerance did not include control groups. A wide variety of instruments was used to assess physical function. Conclusions Partial correction of anemia through ESA treatment has a consistent and positive impact on VO2peak. ESA treatment improves patient- and clinician-assessed physical functioning. The role of erythropoiesis-stimulating agents (ESAs) in treating the anemia of chronic kidney disease has been reevaluated in view of recent studies suggesting that the use of these agents may be associated with increased morbidity and mortality. This potential increased risk needs to be weighed against the potential benefit of ESAs in improving various aspects of health-related quality of life, in particular, exercise tolerance and physical functioning. A systematic review and meta-analysis of exercise tolerance and physical functioning. Adults on maintenance dialysis therapy. Outcomes measured before and after ESA treatment were required. Studies of physical function were required to include at least 25 participants. Treatment with any ESA. Exercise tolerance measured using VO2peak (oxygen consumption per minute at the peak workload during the test), duration of exercise, or 6-minute walk distance or physical functioning assessed using ≥ 1 patient- or clinician-reported outcome measure that included a physical function domain. 28 articles met criteria for inclusion for evaluation of exercise tolerance, and 14 articles, for physical function. Meta-analysis showed a 23.8% increase in VO2peak from before to after erythropoietin therapy initiation (15 studies) and a nonsignificant 8.2% increase comparing a higher with a lower hemoglobin target (3 studies). For physical functioning, 4 studies met criteria for inclusion in the meta-analysis: there was a 10.5% increase in Karnofsky score from before to after erythropoietin therapy initiation. Many studies of exercise tolerance did not include control groups. A wide variety of instruments was used to assess physical function. Partial correction of anemia through ESA treatment has a consistent and positive impact on VO2peak. ESA treatment improves patient- and clinician-assessed physical functioning." @default.
• W2023647184 created "2016-06-24" @default.
• W2023647184 creator A5001054264 @default.
• W2023647184 creator A5028413089 @default.
• W2023647184 creator A5070379392 @default.
• W2023647184 creator A5076406808 @default.
• W2023647184 creator A5080500263 @default.
• W2023647184 creator A5082972280 @default.
• W2023647184 date "2010-03-01" @default.
• W2023647184 modified "2023-10-01" @default.
• W2023647184 title "Systematic Review and Meta-analysis of Exercise Tolerance and Physical Functioning in Dialysis Patients Treated With Erythropoiesis-Stimulating Agents" @default.
• W2023647184 cites W1518465361 @default.
• W2023647184 cites W1963824520 @default.
• W2023647184 cites W1964430734 @default.
• W2023647184 cites W1964576189 @default.
• W2023647184 cites W1967445628 @default.
• W2023647184 cites W1968825436 @default.
• W2023647184 cites W1971258278 @default.
• W2023647184 cites W1975285483 @default.
• W2023647184 cites W1983659087 @default.
• W2023647184 cites W1988769734 @default.
• W2023647184 cites W1989853418 @default.
• W2023647184 cites W1990593626 @default.
• W2023647184 cites W1993840850 @default.
• W2023647184 cites W2004180483 @default.
• W2023647184 cites W2006331513 @default.
• W2023647184 cites W2006444286 @default.
• W2023647184 cites W2011510235 @default.
• W2023647184 cites W2019368602 @default.
• W2023647184 cites W2021802194 @default.
• W2023647184 cites W2025621654 @default.
• W2023647184 cites W2028319677 @default.
• W2023647184 cites W2028963317 @default.
• W2023647184 cites W2029883040 @default.
• W2023647184 cites W2034629579 @default.
• W2023647184 cites W2035054190 @default.
• W2023647184 cites W2040029744 @default.
• W2023647184 cites W2040557090 @default.
• W2023647184 cites W2049255341 @default.
• W2023647184 cites W2053040709 @default.
• W2023647184 cites W2055200227 @default.
• W2023647184 cites W2055451549 @default.
• W2023647184 cites W2063123824 @default.
• W2023647184 cites W2079707047 @default.
• W2023647184 cites W2080769307 @default.
• W2023647184 cites W2086599987 @default.
• W2023647184 cites W2087724260 @default.
• W2023647184 cites W2088293785 @default.
• W2023647184 cites W2093344808 @default.
• W2023647184 cites W2095161817 @default.
• W2023647184 cites W2103517401 @default.
• W2023647184 cites W2108582978 @default.
• W2023647184 cites W2110020738 @default.
• W2023647184 cites W2113615362 @default.
• W2023647184 cites W2118133142 @default.
• W2023647184 cites W2129349191 @default.
• W2023647184 cites W2134487085 @default.
• W2023647184 cites W2136806584 @default.
• W2023647184 cites W2140188175 @default.
• W2023647184 cites W2141456669 @default.
• W2023647184 cites W2151231052 @default.
• W2023647184 cites W2152183263 @default.
• W2023647184 cites W2157541288 @default.
• W2023647184 cites W2159210825 @default.
• W2023647184 cites W2169266039 @default.
• W2023647184 cites W2196974557 @default.
• W2023647184 cites W2312215375 @default.
• W2023647184 cites W2394966499 @default.
• W2023647184 cites W297462666 @default.
• W2023647184 doi "https://doi.org/10.1053/j.ajkd.2009.12.018" @default.
• W2023647184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20133033" @default.
• W2023647184 hasPublicationYear "2010" @default.
• W2023647184 type Work @default.
• W2023647184 sameAs 2023647184 @default.
• W2023647184 citedByCount "73" @default.
• W2023647184 countsByYear W20236471842012 @default.
• W2023647184 countsByYear W20236471842013 @default.
• W2023647184 countsByYear W20236471842014 @default.
• W2023647184 countsByYear W20236471842015 @default.
• W2023647184 countsByYear W20236471842016 @default.
• W2023647184 countsByYear W20236471842017 @default.
• W2023647184 countsByYear W20236471842018 @default.
• W2023647184 countsByYear W20236471842019 @default.
• W2023647184 countsByYear W20236471842020 @default.
• W2023647184 countsByYear W20236471842021 @default.
• W2023647184 countsByYear W20236471842022 @default.
• W2023647184 countsByYear W20236471842023 @default.
• W2023647184 crossrefType "journal-article" @default.
• W2023647184 hasAuthorship W2023647184A5001054264 @default.
• W2023647184 hasAuthorship W2023647184A5028413089 @default.
• W2023647184 hasAuthorship W2023647184A5070379392 @default.
• W2023647184 hasAuthorship W2023647184A5076406808 @default.
• W2023647184 hasAuthorship W2023647184A5080500263 @default.
• W2023647184 hasAuthorship W2023647184A5082972280 @default.
• W2023647184 hasConcept C126322002 @default.
• W2023647184 hasConcept C159110408 @default.
• W2023647184 hasConcept C177713679 @default.
• W2023647184 hasConcept C1862650 @default.

• next